Drug company Bayer has agreed to a $3.3 million settlement after being sued for associating prostate-cancer claims with its One A Day Men’s Health vitamins. The suit was settled between Bayer and attorneys general from California, Illinois, and Oregon.
Drug company Bayer has agreed to a $3.3 million settlement after being sued for associating prostate-cancer claims with its One A Day Men’s Health vitamins. The suit was settled between Bayer and attorneys general from California, Illinois, and Oregon.
Oregon attorney general John Kroger accused Bayer of “deceptively leveraging fear of prostate cancer” to market its men’s health vitamins. According to the New York Times, marketing statements on the vitamins’ packaging included: “Did you know that prostate cancer is the most frequently diagnosed cancer in men and that emerging research suggests selenium may reduce the risk of prostate cancer?”
Bayer had also partnered with Major League Baseball on a “Strike Out Prostate Cancer” campaign, the newspaper reported.
According to the Center for Science in the Public Interest (CSPI), while Bayer claimed that “emerging research” showed that selenium may reduce the risk of prostate cancer, the company showed insufficient scientific evidence of this relationship. Contrarily, CSPI points to a seven-year, 35,000-subject, $118-million study funded by the National Institutes of Health that found that selenium does not prevent prostate cancer in healthy men-and that it may have contributed to an increase in diabetes.
Nutritional Outlook Announces its 2024 Best of the Industry Award Winners
December 13th 2024Every year, Nutritional Outlook chooses its Best of the Industry Award winners, recognizing individuals, groups, and companies whose initiatives today may help shape, for the better, the state of the dietary supplement and food and beverage industries for years to come. This year's winners are...
Balchem’s Newest Launch Optifolin+® Brings Innovation to the Folate Market
November 15th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin+®, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.